leisure time -WSS

leisure time

author：leisure time 2025-09-06 01:58:09 - browse：2

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Head of FDA's diagnostics center, who led through Covid, retires

WSS

The biotech scorecard for Q4: 16 stock

6 solutions to address cancer drug shortages and others

IVG is promising — but it won’t replace IVF quite yet

Printout prescription drug information shouldn’t go digital

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Prior authorization reform is both possible and imperative

leisure time

leisure time

entertainment

Apple is now the first public company to be valued at $3 trillion

WHO recommends second malaria vaccine

Wildfire smoke exposes gaps in outdoor worker protections

RSV injection headlines need to be accurate for good uptake

Cancer drug shortages should be causing more outrage

Experts study whether long Covid risk adds up with each reinfection

Supreme Court strikes down use of affirmative action

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

The cancer drug shortage isn’t new — and neither are the solutions

What we owe ALS patients — and why one company fell short

leisure time

Head of FDA's diagnostics center, who led through Covid, retires

Flu, Covid vaccination rates decline, new survey data show

What causes osteoarthritis? Researchers study link to brain protein

Health insurers' Q3 question: how much care are people getting?

IVG is promising — but it won’t replace IVF quite yet

Immunocompromised patients offer clues on chronic Covid

focus

knowledge

entertainment

explore